As the number of deaths in the United States involving overdoses of prescription opioid medications continues a decade-long increase, a multidisciplinary group of clinicians is calling on the US Food and Drug Administration (FDA) to revise the labels of these drugs. They argue that aggressive marketing of painkillers for chronic noncancer pain has contributed to this ongoing public health crisis, despite limited evidence supporting the safety and efficacy of these medications for patients with chronic noncancer pain.
Kuehn BM. Petition Targets Painkiller Marketing in Effort to Curb Overdose Deaths. JAMA. 2012;308(12):1194–1196. doi:10.1001/2012.jama.11248
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: